Study summary

The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.

Additional Study Details

Phase
Phase 3
Product
  • Placebo
  • Type
    Interventional
    Masking
    Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
    Enrollment number
    514
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English
    Protocol
    Available Language(s): English
    Statistical Analysis Plan (SAP)
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP81001
      Fukuoka, Fukuoka, Japan
      Completed
      Site US10036
      Rochester, MN, United States, 55905
      Completed
      Site US10024
      Seattle, WA, United States, 98109
      Completed
      Site JP81003
      Nagoya, Aichi, Japan
      Withdrawn
      Site DE49003
      Wiesbaden, Germany, 65191
      Withdrawn
      Site US10029
      Winston-Salem, NC, United States, 27157
      Completed
      Site US10025
      Chapel Hill, NC, United States, 27514
      Completed
      Site JP81005
      Fukuoka, Fukuoka, Japan
      Completed
      Site KR82004
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 06351
      Completed
      Site FR33010
      Nice, France, 06200
      Completed
      Site US10039
      Seattle, WA, United States, 98108
      Completed
      Site KR82003
      Seoul, Republic of Korea, 110744
      Completed
      Site BE32005
      Leuven, Belgium, 3000
      Completed
      Site JP81009
      Minato-ku, Tokyo, Japan
      Completed
      Site US10028
      Birmingham, AL, United States, 35294
      Completed
      Site DE49008
      Tuebingen, Germany, 72076
      Completed
      Site KR82001
      Seoul, Republic of Korea, 137-701
      Completed
      Site ES34003
      Granada, Spain, 18012
      Completed
      Site US10046
      Salt Lake City, UT, United States, 84143
      Completed
      Site US10031
      Richmond, VA, United States, 23298
      Withdrawn
      Site ES34012
      Barcelona, Spain, 08036
      Completed
      Site DE49007
      Muenster, Germany, 48149
      Completed
      Site DE49014
      Koln, Germany, 50937
      Completed
      Site JP81007
      Sapporo, Hokkaido, Japan
      Completed
      Site TW88602
      Taipei City, Taiwan, Province of China, 11217
      Completed
      Site DE49001
      Wurzburg, Germany, 97080
      Completed
      Site US10016
      Nashville, TN, United States, 37232
      Completed
      Site US10002
      Dallas, TX, United States, 75246
      Completed
      Site CA15001
      Vancouver, BC, Canada, V5Z 1M9
      Withdrawn
      Site US10009
      Houston, TX, United States, 77030
      Completed
      Site US10042
      St. Louis, MO, United States, 63110
      Completed
      Site US10010
      Louisville, KY, United States, 40202
      Withdrawn
      Site US10033
      Portland, OR, United States, 97239
      Completed
      Site US10019
      Milwaukee, WI, United States, 53226
      Completed
      Site US10030
      Tampa, FL, United States, 33612
      Completed
      Site US10012
      Atlanta, GA, United States, 30322
      Withdrawn
      Site DE49004
      Jena, Germany, 07740
      Withdrawn
      Site FR33004
      Paris, France, 75010
      Withdrawn
      Site US10037
      Chicago, IL, United States, 60637
      Completed
      Site US10027
      Rochester, NY, United States, 14642
      Completed
      Site DE49012
      Dusseldorf, Germany, 40225
      Completed
      Site US10045
      Houston, TX, United States, 77030
      Completed
      Site AU43001
      Herston, QLD, Australia, QLD 4029
      Withdrawn
      Site BE32006
      Gent, Belgium, 9000
      Completed
      Site US10007
      Indianapolis, IN, United States, 46237
      Completed
      Site US10020
      Westwood, KS, United States, 66205
      Completed
      Site ES34004
      Barcelona, Spain, 08908
      Completed
      Site FR33011
      Besancon, France, 25030
      Completed
      Site US10011
      Baltimore, MD, United States, 21205
      Completed
      Site CA15004
      Montreal, QC, Canada, H2W 1S6
      Completed
      Site US10043
      Baltimore, MD, United States, 21201
      Completed
      Site CA15003
      Quebec, QC, Canada, G1R 2J6
      Completed
      Site JP81011
      Maebashi, Gunma, Japan
      Withdrawn
      Site AU43002
      Melbourne, VIC, Australia, VIC 3004
      Completed
      Site DE49015
      Mainz, Germany, 55131
      Completed
      Site FR33009
      Nantes, France, 44093
      Completed
      Site ES34011
      Madrid, Spain, 28028
      Completed
      Site US10047
      New York, NY, United States, 10032
      Withdrawn
      Site US10040
      Chicago, IL, United States, 60611
      Completed
      Site SE46001
      Gothenburg, Sweden, 413 45
      Completed
      Site AU43004
      Adelaide, SA, Australia, SA 5000
      Completed
      Site ES34010
      Salamanca, Spain, 37007
      Completed
      Site FR33005
      Creteil, France, 94000
      Completed
      Site DE49002
      Leipzig, Germany, 04103
      Completed
      Site US10026
      Stanford, CA, United States, 94305
      Completed
      Site ES34007
      Murcia, Spain, 30008
      Completed
      Site DE49010
      Bonn, Germany, 53127
      Completed
      Site TW88601
      Taipei City, Taiwan, Province of China, 10002
      Completed
      Site ES34006
      Barcelona, Spain, 08041
      Completed
      Site SE46004
      Lund, Sweden, 221 85
      Completed
      Site SE46005
      UMEA, Sweden, 901 85
      Completed
      Site BE32007
      Roeselare, Belgium, 8800
      Completed
      Site SE46006
      Linkoping, Sweden, 581 85
      Completed
      Site US10044
      Tucson, AZ, United States, 85724
      Completed
      Site ES34009
      Valencia, Spain, 46010
      Completed
      Site ES34001
      Badalona, Spain, 08615
      Completed
      Site DE49006
      Ulm, Germany, 89081
      Completed
      Site CA15002
      Toronto, ON, Canada, M5G 2M9
      Completed
      Site ES34005
      Cordoba, Spain, 14004
      Completed
      Site TW88603
      Taoyuan County, Taiwan, Province of China, 33305
      Completed
      Site JP81004
      Shinjuku-ku, Tokyo, Japan
      Completed
      Site US10013
      Chicago, IL, United States, 60612
      Completed
      Site US10021
      Boston, MA, United States, 02114
      Completed
      Site ES34002
      Santander, Spain, 39008
      Completed
      Site JP81010
      Bunkyo-ku, Tokyo, Japan
      Completed
      Site DE49013
      Gottingen, Germany, 37075
      Completed
      Site SE46003
      Stockholm, Sweden, 14186
      Withdrawn
      Site AU43003
      Parkville, VIC, Australia, VIC, 3050
      Completed
      Site DE49005
      Stuttgart, Germany, 70376
      Completed
      Site US10035
      San Francisco, CA, United States, 94143
      Completed
      Site JP81006
      Osaka, Osaka, Japan
      Completed
      Site JP81008
      Chuo-ku, Tokyo, Japan
      Completed
      Site BE32001
      Brugge, Belgium, 8000
      Completed
      Site US10023
      Hackensack, NJ, United States, 07601-2105
      Completed
      Site KR82002
      Seoul, Republic of Korea, 05505

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?